Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
INNOVATE Corp (VATE)
NYSEIndustrialsEngineering & ConstructionSnapshot 2026-11-04
$4.97-8.47%
Close 2026-11-05 · 1-day change
NYSEIndustrialsEngineering & ConstructionSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
35.79 → 35.79 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for VATE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Capital allocation supports financial stability and buybacks | The company announced share buybacks, signaling capital return focus. | Intact | Company halts buybacks or increases debt unsustainably | Buyback activity maintained (qualitative) VATE announced a share buyback on 2026-10-09. Debt issuance and acquisition completed in Oct 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
VATE is a high-risk, cyclical business with growth from DBM Global and developing Life Sciences operations. The long-term thesis is intact, and recent financial performance is strong, but the company remains loss-making overall and management is rated volatile.
The valuation evidence points to VATE being cheap versus peers, while the model’s confidence is low. The priced-in signal is tagged as justified, with low fragility, but the negative expectations gap suggests the market’s assumptions remain a concern rather than a clear source of support.
Near term, recent results show strong progress at DBM Global, including higher revenue and backlog, while Life Sciences has advanced commercialization and regulatory work. The October sale of DBM Global brought cash and stock consideration, and management says it intends to use net proceeds to reduce debt; execution is mixed so far, and the next report carries risk given recent misses and the company’s smaller size.
Over the multi-year view, the thesis depends on whether growth and margin progress at DBM Global and Life Sciences can translate into stronger company-wide results, alongside effective debt reduction. Near term, continued strength from Industrials bellwethers could support the sector backdrop, while weaker bellwether results or a weakening jobs trend could add pressure to cyclical businesses.
For the next 1 to 3 years, VATE combines strong recent operating progress with meaningful uncertainty from losses, high risk, and execution. The thesis remains intact, but depends on sustained business progress and balance-sheet improvement. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| INNOVATE Corp aims to improve operating income and cash flow. |
| Broken |
| Cash from operating activities falls below $45 million in 2026-Q2 |
Cash from operations: $-24.6M FY2026-Q2; GAAP. Published target: >=45.5 million USD. The target does not explicitly identify fiscal versus calendar quarters. Aug 6, 2026-24,600,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improves to at least $10M next quarter | Operating income was $10M in 2026-Q1, up from $6.1M in 2025-Q3. | Broken | Operating income falls below $10 million in 2026-Q2 | Operating income: $34.5M FY2026-Q2; GAAP. Published target: >=10 million USD. The target does not explicitly identify fiscal versus calendar quarters. Aug 6, 202634,500,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$35.79 → $35.79 · observed estimates
$1.94B → $1.94B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-07-25 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-07-26 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-07-27 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-07-28 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-07-29 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-07-30 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-07-31 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-01 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-02 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-03 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-04 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-05 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-06 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-08 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-09 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-10 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-12 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-13 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-14 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-15 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-16 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-17 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-18 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-19 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-20 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-21 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-22 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-23 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-24 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-25 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-26 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-27 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-28 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-29 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-30 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-08-31 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-01 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-02 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-03 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-04 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-05 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-06 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-07 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-08 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-09 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-10 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-11 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-12 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-13 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-14 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-15 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-16 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-17 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-18 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-19 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-20 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-21 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-22 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-23 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-24 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-25 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-26 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-27 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-28 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-29 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-09-30 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-01 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-02 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-03 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-04 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-05 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-06 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-07 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-08 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-09 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-10 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-11 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-12 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-13 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-14 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-15 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-16 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-17 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-18 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-19 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-20 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-21 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-22 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-23 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-24 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-25 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-26 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-27 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-28 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-29 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-30 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-10-31 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-11-01 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-11-02 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-11-03 | $35.79 | $1,939,110,000 | 1 / 1 |
| 2026-11-04 | $35.79 | $1,939,110,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.